HCG on TRT: How It Preserves Fertility and Testicular Function (Dosing, Protocols, and the Evidence)

What does HCG do on TRT?

HCG on TRT is most commonly used to preserve testicular function and fertility that exogenous testosterone would otherwise suppress. Human chorionic gonadotropin (HCG) is a glycoprotein hormone that binds the same receptor as luteinizing hormone (LH) on testicular Leydig cells. By acting as an LH-analog, HCG keeps the testes producing intratesticular testosterone (ITT) — the high local concentration required for sperm production — even when the brain has stopped sending its own LH signal because of exogenous testosterone.

In practical terms, men on TRT add HCG for one or more of three reasons: to maintain spermatogenesis (current or future fertility), to preserve testicular volume, and in some cases to improve testicular pain or feeling of testicular "shutdown." The clinical evidence supporting each of these uses differs in strength, and the decision to add HCG is always a prescriber-led decision.

For background on how testosterone therapy works in general, see our TRT 101 pillar guide. For the broader picture of what changes when you stop or alter the system, see coming off TRT and HPTA recovery.

Why does TRT shut down testicular function in the first place?

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis (HPGA, sometimes written HPTA). The hypothalamus senses circulating testosterone and reduces gonadotropin-releasing hormone (GnRH) output. Without GnRH pulses, the pituitary stops releasing LH and FSH. Without LH, the Leydig cells stop producing testosterone in the testes. Without FSH (and without high local intratesticular testosterone), the Sertoli cells cannot support spermatogenesis. Testicular volume, which is mostly seminiferous tubules and Leydig cells, often decreases as a visible consequence.

This is not a defect of TRT — it is the expected pharmacology. Endocrine Society and AUA testosterone guidelines explicitly note that exogenous testosterone suppresses spermatogenesis in most men, which is why fertility preservation is a standard part of pre-treatment counseling for any man who may want biological children in the future.

The result for many men on TRT alone is some combination of: testicular shrinkage (often noticeable within weeks to months), markedly reduced sperm counts that may approach or reach azoospermia, and a feeling of testicular dormancy that some men find uncomfortable. HCG addresses these consequences by re-supplying the LH signal that TRT removed.

What is intratesticular testosterone and why does sperm production require it?

Intratesticular testosterone (ITT) is the testosterone concentration measured directly inside the testes. It is roughly 50 to 100 times higher than serum testosterone in healthy men, and that local concentration is required for normal spermatogenesis. Serum testosterone — the number on a typical blood panel — is far too low to support sperm production on its own. Sperm production depends on the local environment created by Leydig cell testosterone secretion, not on circulating levels.

When TRT raises serum testosterone but suppresses LH, ITT collapses even though serum levels look normal or supraphysiological. This is the central reason TRT alone is not a fertility preservation strategy: a man on TRT can have a serum total testosterone of 900 ng/dL and still have a sperm count near zero, because his ITT has dropped to a tiny fraction of the level required.

HCG restores ITT by stimulating Leydig cells directly. Coviello et al. demonstrated this directly in a controlled study (more on that below). The key insight from that work is that even relatively low HCG doses can keep ITT in a range compatible with spermatogenesis.

What did the Coviello 2005 dose-finding study show?

Coviello AD, Matsumoto AM, Bremner WJ, et al., "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression," Journal of Clinical Endocrinology & Metabolism, 2005, is the foundational dose-finding study cited in nearly every clinical discussion of HCG on TRT.

The investigators recruited healthy young men, suppressed their endogenous gonadotropins with exogenous testosterone enanthate, and randomized them to receive HCG at 0 IU, 125 IU, 250 IU, or 500 IU every other day. They measured intratesticular testosterone by direct testicular fluid sampling — an unusually direct readout for a clinical study.

Key findings reported in the paper:

• Without HCG, intratesticular testosterone fell to roughly 6% of baseline (a dramatic suppression).
• HCG at 125 IU every other day partially restored ITT.
• HCG at 250 IU every other day restored ITT to roughly 26% of baseline.
• HCG at 500 IU every other day restored ITT to approximately baseline levels.

The clinical relevance is that even modest HCG doses, well below those used for ovulation induction in women, are sufficient to preserve a substantial fraction of intratesticular testosterone in men whose pituitary signal has been turned off by exogenous testosterone. This is why doses in the 250 to 500 IU range, given two to three times per week, became the most commonly cited starting points in the male hormone literature. Note: those numbers describe what the study used — they are not a recommended dose for any reader.

Visualizing the Coviello dose-response

The chart below illustrates the relationship between HCG dose and intratesticular testosterone preservation reported in the study. It is a simplified visual aid based on published values, not an interactive lookup tool.

What did Hsieh 2013 show about TRT plus HCG and fertility?

Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI, "Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy," Journal of Urology, 2013, is the most-cited clinical study evaluating low-dose HCG specifically in men on TRT for the purpose of preserving sperm production.

The investigators followed 26 men receiving testosterone replacement (intramuscular, gel, or pellet) with concomitant HCG at 500 IU every other day. They evaluated semen parameters and serum hormones at intervals over a multi-year follow-up window.

Key reported findings:

• None of the 26 men became azoospermic during follow-up.
• Serum testosterone levels remained in the therapeutic range as expected for TRT.
• Sperm concentration, motility, and morphology trends were not significantly different from baseline.
• Pregnancies were achieved in some couples during the study window.

Hsieh 2013 is observational and small. It does not prove that HCG guarantees fertility on TRT, and it does not directly compare HCG-plus-TRT to TRT alone in a randomized design. What it does provide is the clearest published clinical signal that the Coviello-derived 500 IU every-other-day strategy is associated with preserved spermatogenesis in real men using TRT in routine practice.

Subsequent reviews — including chapters in Campbell-Walsh-Wein Urology and consensus papers from male reproductive medicine groups — generally cite Coviello and Hsieh together as the evidentiary basis for the typical HCG-with-TRT protocol.

What HCG dosing ranges does the literature report?

The published literature most commonly reports HCG doses in the 250 to 500 IU range, given subcutaneously or intramuscularly two to three times per week, when used alongside TRT for fertility or testicular function preservation. Specific protocols described in research and clinical reviews include:

Reported dosing ranges from published sources

The numbers above describe what published research and clinical reviews report. They are not a recommended dose for any individual reader. Specific dosing decisions belong to your prescriber.

Why the wide range? Because the clinical goal varies. A man on long-term TRT trying to preserve testicular volume and a baseline fertility insurance policy often does well at the lower end of the literature range. A man with hypogonadotropic hypogonadism actively trying to conceive after stopping TRT typically needs higher doses, sometimes combined with recombinant FSH, to drive complete spermatogenic recovery. These are different clinical situations with different protocols.

Does HCG actually preserve testicular volume on TRT?

Testicular volume preservation is one of the most commonly observed effects of HCG on TRT. Because Leydig cells (and the seminiferous tubule architecture they support) make up most of testicular mass, restoring LH-like stimulation through HCG often slows or reverses the testicular atrophy that occurs on TRT alone.

A representative scenario: a man six months into TRT-only notices his testicles are noticeably smaller and feel different. After starting HCG at a typical literature-range dose, he reports a return toward pre-TRT volume within roughly 4 to 12 weeks. This trajectory is widely described in clinical practice and is consistent with HCG's mechanism, though individual response varies.

Important caveats:

• Volume return is not the same as fertility return. A testis can re-enlarge while sperm parameters lag — testicular size correlates loosely with spermatogenic output, not perfectly.
• Very long-duration suppression may reduce the chance of full restoration in some men, though data here is limited.
• Pre-existing primary testicular dysfunction (Klinefelter syndrome, prior chemotherapy, varicocele complications) changes the response profile.

Testicular volume by itself is a soft endpoint — the clinical questions that matter more are sperm parameters (if fertility is the goal), serum hormone profile, and symptom response.

What are the side effects and monitoring considerations for HCG on TRT?

HCG is generally well tolerated at the low doses used alongside TRT, but it has a side effect and monitoring profile of its own. The most commonly reported considerations include:

Reported side effects

• Estradiol elevation. HCG drives additional Leydig cell testosterone production, which is then partially aromatized. Sensitive estradiol can rise after starting HCG. See our estradiol on TRT article for context on E2 monitoring.
• Acne and oily skin. Driven by the additional androgen output from the testes.
• Mood changes. Both directions reported — some men report feeling better, others note irritability.
• Injection site reactions. Mild and usually transient with subcutaneous administration.
• Gynecomastia risk. Indirect, via the E2 rise, particularly at higher doses.
• Down-regulation of LH receptors. Theoretical with chronic high-dose use; relevance at typical low TRT-adjunct doses is uncertain.

Typical monitoring discussed in clinical reviews

• Sensitive estradiol, total testosterone, and SHBG after starting or adjusting HCG
• Semen analysis when fertility preservation is the goal
• Hematocrit on the same TRT monitoring schedule
• Clinical symptom check-in for acne, mood, gyno signs

What are the alternatives to HCG on TRT? (Clomiphene, enclomiphene, FSH)

HCG is not the only option for preserving fertility or testicular function during or instead of TRT. The major alternatives, each with a different mechanism and use-case, are summarized below.

Clomiphene citrate (Clomid)

Clomiphene is an oral selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus. The result is increased GnRH, LH, and FSH output, which raises endogenous testosterone and supports spermatogenesis. Clomiphene is most commonly used as monotherapy for secondary hypogonadism rather than as an add-on to TRT. Because clomiphene works upstream, it is incompatible with the suppressive effect of exogenous testosterone — a man on full TRT will typically not benefit from clomiphene because the brain is already shut down. For a deeper comparison see our Clomid vs TRT article.

Enclomiphene

Enclomiphene is the trans-isomer of clomiphene. It has the LH/FSH-raising effect without much of the estrogenic activity associated with the cis-isomer (zuclomiphene). Like clomiphene, it is most useful as monotherapy for secondary hypogonadism and is generally not combined with full-dose TRT. Compare in our enclomiphene vs TRT article.

Recombinant FSH (rFSH) and HMG

Recombinant follicle-stimulating hormone (or human menopausal gonadotropin, which contains FSH activity) is sometimes added to HCG when HCG alone does not produce adequate spermatogenesis — typically in men with hypogonadotropic hypogonadism trying to conceive. Adding FSH is more common in dedicated fertility induction protocols than in routine TRT-adjunct use.

Side-by-side mechanism comparison

If you are actively trying to conceive on TRT

Active conception attempts while on TRT are a specific clinical situation that deserves dedicated reproductive guidance. The general framework discussed in male reproductive medicine literature includes:

1. Baseline semen analysis. Two semen analyses are typically recommended to characterize baseline before any treatment change.
2. Hormone evaluation. Total and free testosterone, LH, FSH, estradiol, prolactin, and thyroid function are commonly assessed.
3. TRT discontinuation or HCG addition. Some men can conceive on TRT plus HCG; others may need to discontinue TRT temporarily and use a fertility-restoration regimen (HCG, sometimes with FSH or a SERM) until pregnancy is achieved.
4. Reproductive endocrinology referral. Especially if recovery is slow, partner factors are present, or assisted reproductive technology is being considered.
5. Sperm cryopreservation. Banking sperm before starting TRT is the highest-confidence fertility insurance policy and is often discussed with men who may want children later.

Recovery times from TRT-induced spermatogenic suppression vary widely. Reviews in Fertility and Sterility and the Journal of Urology have reported recovery to baseline sperm parameters within roughly 6 to 24 months for most men after TRT cessation, but a meaningful minority experience prolonged or incomplete recovery. The duration of TRT, age, and underlying testicular function all matter. The companion article on coming off TRT discusses the broader HPTA recovery picture.

What do the Endocrine Society and AUA guidelines say about HCG on TRT?

The major clinical guidelines on testosterone therapy address fertility preservation, though they do not prescribe specific HCG protocols.

The 2018 Endocrine Society clinical practice guideline (Bhasin S et al., Journal of Clinical Endocrinology & Metabolism) discusses the suppression of spermatogenesis by exogenous testosterone and recommends that men who wish to maintain fertility either avoid TRT or use alternative approaches such as gonadotropins (HCG, with or without FSH) instead of, or in addition to, exogenous testosterone. The guideline does not endorse a specific HCG dose for this purpose.

The AUA testosterone deficiency guideline (Mulhall JP et al., 2018, updated 2024) similarly emphasizes that exogenous testosterone suppresses spermatogenesis and that men interested in current or future fertility should be counseled about gonadotropin-based alternatives. The AUA guideline supports the use of HCG (and SERMs) in appropriate clinical contexts but does not prescribe specific dosing.

The American Society for Reproductive Medicine (ASRM) and Society for the Study of Male Reproduction (SSMR) have published practice committee opinions and reviews further detailing protocols for fertility preservation and induction in men on or off TRT. These are the documents your prescriber or a reproductive endocrinologist is most likely to reference for protocol-level decisions.

For the broader cardiovascular safety picture of TRT itself, see our TRAVERSE trial breakdown. For day-to-day blood work interpretation, see our estradiol on TRT and hematocrit on TRT companions.

Conceptual visual: where HCG and SERMs act on the HPGA

The bottom line: talk to your prescriber

HCG on TRT is one of the most evidence-supported strategies for preserving testicular function and fertility during testosterone replacement. Coviello 2005 established that low HCG doses can keep intratesticular testosterone in a range compatible with spermatogenesis. Hsieh 2013 showed that men on TRT plus 500 IU every other day generally maintained semen parameters in real-world use. Major guidelines acknowledge gonadotropin therapy as the appropriate route for men who want to preserve fertility while on TRT.

What this article does not do is tell you what to take. HCG is prescription-only. Specific dosing, frequency, duration, monitoring, and the decision to combine it with TRT — or to use an alternative like enclomiphene, clomiphene, or an FSH-containing protocol — depend on your goals, your labs, your fertility timeline, your comorbidities, and your prescriber's clinical judgment.

If you are on TRT and have concerns about fertility, testicular volume, or testicular function, the next step is a conversation with the prescriber managing your therapy. If you are actively trying to conceive or considering it within the next several years, ask whether a referral to a urologist or reproductive endocrinologist with male reproductive medicine experience is appropriate.